Selective inhibition of EZH2 and EZH1 enzymatic activity by a small molecule suppresses MLL-rearranged leukemia

Blood

Volumn 125, Issue 2, 2015, Pages 346-357

  Xu, Bowen ^a   On, Doan M ^a   Ma, Anqi ^b   Parton, Trevor ^b   Konze, Kyle D ^b   Pattenden, Samantha G ^c   Allison, David F ^a   Cai, Ling ^a   Rockowitz, Shira ^d   Liu, Shichong ^e   Liu, Ying ^f   Li, Fengling ^g   Vedadi, Masoud ^g   Frye, Stephen V ^a,c   Garcia, Benjamin A ^e   Zheng, Deyou ^d   Jin, Jian ^b   Wang, Gang Greg ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f WEILL CORNELL MEDICAL COLLEGE   (United States)

^g UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DIMETHYL SULFOXIDE; POLYCOMB REPRESSIVE COMPLEX 2; SPACER DNA; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR EZH1; TRANSCRIPTION FACTOR EZH2; TRANSCRIPTOME; UNC 1999; UNC 2400; UNCLASSIFIED DRUG; ENZYME INHIBITOR; EZH1 PROTEIN, MOUSE; EZH2 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL VIABILITY; CHROMATIN IMMUNOPRECIPITATION; COLONY FORMING UNIT; CONTROLLED STUDY; DOWN REGULATION; ECTODERM; ENHANCER REGION; ENZYME ACTIVITY; FLOW CYTOMETRY; GENE ONTOLOGY; GENE SILENCING; GENOMICS; HISTONE ACETYLATION; HISTONE METHYLATION; HYDROGEN BOND; IMMUNOBLOTTING; LEUKEMIA; LEUKOCYTE COUNT; MASS SPECTROMETRY; MIXED LINEAGE LEUKEMIA; MOUSE; MURINE LEUKEMIA; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEOMICS; STAINING; UPREGULATION; WILD TYPE; WRIGHT GIEMSA STAINING; ACUTE BIPHENOTYPIC LEUKEMIA; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; DISEASE MODEL; DNA MICROARRAY; ENZYMOLOGY; KNOCKOUT MOUSE; REAL TIME POLYMERASE CHAIN REACTION;

ANIMALS; ANTINEOPLASTIC AGENTS; CHROMATIN IMMUNOPRECIPITATION; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; IMMUNOBLOTTING; LEUKEMIA, BIPHENOTYPIC, ACUTE; MASS SPECTROMETRY; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYCOMB REPRESSIVE COMPLEX 2; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 84921000037     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-06-581082     Document Type: Article

References (55)

1. Chi P, Allis CD, Wang GG. Covalent histone modifications-miswritten, misinterpreted and mis-erased in human cancers. Nat Rev Cancer. 2010;10(7):457-469.
2. Strahl BD, Allis CD. The language of covalent histone modifications. Nature. 2000;403(6765):41-45.
3. Greer EL, Shi Y. Histone methylation: a dynamic mark in health, disease and inheritance. Nat Rev Genet. 2012;13(5):343-357.
4. Esteller M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet. 2007;8(4):286-298.
5. Karberg S. Switching on epigenetic therapy. Cell. 2009;139(6):1029-1031.
6. Dawson MA, Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell. 2012;150(1):12-27.
7. Arrowsmith CH, Bountra C, Fish PV, Lee K, Schapira M. Epigenetic protein families: a new frontier for drug discovery. Nat Rev Drug Discov. 2012;11(5):384-400.
8. Helin K, Dhanak D. Chromatin proteins and modifications as drug targets. Nature. 2013;502(7472):480-488.
9. Margueron R, Li G, Sarma K, et al. Ezh1 and Ezh2 maintain repressive chromatin through different mechanisms. Mol Cell. 2008;32(4):503-518.
10. Mochizuki-Kashio M, Mishima Y, Miyagi S, et al. Dependency on the polycomb gene Ezh2 distinguishes fetal from adult hematopoietic stem cells. Blood. 2011;118(25):6553-6561.
11. Hidalgo I, Herrera-Merchan A, Ligos JM, et al. Ezh1 is required for hematopoietic stem cell maintenance and prevents senescence-like cell cycle arrest. Cell Stem Cell. 2012;11(5):649-662.
12. Caganova M, Carrisi C, Varano G, et al. Germinal center dysregulation by histone methyltransferase EZH2 promotes lymphomagenesis. J Clin Invest. 2013;123(12):5009-5022.
13. Béguelin W, Popovic R, Teater M, et al. EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer Cell. 2013;23(5):677-692.
14. Morin RD, Johnson NA, Severson TM, et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet. 2010;42(2):181-185.
15. Sneeringer CJ, Scott MP, Kuntz KW, et al. Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas. Proc Natl Acad Sci USA. 2010;107(49):20980-20985.
16. Herrera-Merchan A, Arranz L, Ligos JM, de Molina A, Dominguez O, Gonzalez S. Ectopic expression of the histone methyltransferase Ezh2 in haematopoietic stem cells causes myeloproliferative disease. Nat Commun. 2012;3:623.
17. Berg T, Thoene S, Yap D, et al. A transgenic mouse model demonstrating the oncogenic role of mutations in the polycomb-group gene EZH2 in lymphomagenesis. Blood. 2014;123(25):3914-3924.
18. Shen X, Liu Y, Hsu Y-J, et al. EZH1 mediates methylation on histone H3 lysine 27 and complements EZH2 in maintaining stem cell identity and executing pluripotency. Mol Cell. 2008;32(4):491-502.
19. Neff T, Sinha AU, Kluk MJ, et al. Polycomb repressive complex 2 is required for MLL-AF9 leukemia. Proc Natl Acad Sci USA. 2012;109(13):5028-5033.
20. Shi J, Wang E, Zuber J, et al. The Polycomb complex PRC2 supports aberrant self-renewal in a mouse model of MLL-AF9;Nras(G12D) acute myeloid leukemia. Oncogene. 2013;32(7):930-938.
21. Knutson SK, Wigle TJ, Warholic NM, et al. A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nat Chem Biol. 2012;8(11):890-896.
22. McCabe MT, Ott HM, Ganji G, et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature. 2012;492(7427):108-112.
23. Qi W, Chan H, Teng L, et al. Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation. Proc Natl Acad Sci USA. 2012;109(52):21360-21365.
24. Knutson SK, Kawano S, Minoshima Y, et al. Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma. Mol Cancer Ther. 2014;13(4):842-854.
25. Konze KD, Ma A, Li F, et al. An orally bioavailable chemical probe of the lysine methyltransferases EZH2 and EZH1. ACS Chem Biol. 2013;8(6):1324-1334.
26. Dou Y, Hess JL. Mechanisms of transcriptional regulation by MLL and its disruption in acute leukemia. Int J Hematol. 2008;87(1):10-18.
27. Krivtsov AV, Armstrong SA. MLL translocations, histone modifications and leukaemia stem-cell development. Nat Rev Cancer. 2007;7(11):823-833.
28. Slany RK. The molecular biology of mixed lineage leukemia. Haematologica. 2009;94(7):984-993.
29. Tanaka S, Miyagi S, Sashida G, et al. Ezh2 augments leukemogenicity by reinforcing differentiation blockage in acute myeloid leukemia. Blood. 2012;120(5):1107-1117.
30. Lin S, Garcia BA. Examining histone posttranslational modification patterns by highresolution mass spectrometry. Methods Enzymol. 2012;512:3-28.
31. Wang GG, Song J, Wang Z, et al. Haematopoietic malignancies caused by dysregulation of a chromatin-binding PHD finger. Nature. 2009;459(7248):847-851.
32. Wang GG, Cai L, Pasillas MP, Kamps MP. NUP98-NSD1 links H3K36 methylation to Hox-A gene activation and leukaemogenesis. Nat Cell Biol. 2007;9(7):804-812.
33. Wang GG, Calvo KR, Pasillas MP, Sykes DB, Häcker H, Kamps MP. Quantitative production of macrophages or neutrophils ex vivo using conditional Hoxb8. Nat Methods. 2006;3(4):287-293.
34. Cai L, Rothbart SB, Lu R, et al. An H3K36 methylation-engaging Tudor motif of polycomblike proteins mediates PRC2 complex targeting. Mol Cell. 2013;49(3):571-582.
35. Lee TI, Johnstone SE, Young RA. Chromatin immunoprecipitation and microarray-based analysis of protein location. Nat Protoc. 2006;1(2):729-748.
36. Goldberg AD, Banaszynski LA, Noh KM, et al. Distinct factors control histone variant H3.3 localization at specific genomic regions. Cell. 2010;140(5):678-691.
37. Antonysamy S, Condon B, Druzina Z, et al. Structural context of disease-associated mutations and putative mechanism of autoinhibition revealed by x-ray crystallographic analysis of the EZH2-SET domain. PLoS ONE. 2013;8(12):e84147.
38. Wu H, Zeng H, Dong A, et al. Structure of the catalytic domain of EZH2 reveals conformational plasticity in cofactor and substrate binding sites and explains oncogenic mutations. PLoS ONE. 2013;8(12):e83737.
39. Jung HR, Pasini D, Helin K, Jensen ON. Quantitative mass spectrometry of histones H3.2 and H3.3 in Suz12-deficient mouse embryonic stem cells reveals distinct, dynamic posttranslational modifications at Lys-27 and Lys-36. Mol Cell Proteomics. 2010;9(5):838-850.
40. Pasini D, Malatesta M, Jung HR, et al. Characterization of an antagonistic switch between histone H3 lysine 27 methylation and acetylation in the transcriptional regulation of Polycomb group target genes. Nucleic Acids Res. 2010;38(15):4958-4969.
41. Nagel S, Venturini L, Marquez VE, et al. Polycomb repressor complex 2 regulates HOXA9 and HOXA10, activating ID2 in NK/T-cell lines. Mol Cancer. 2010;9:151.
42. Somervaille TC, Cleary ML. Identification and characterization of leukemia stem cells in murine MLL-AF9 acute myeloid leukemia. Cancer Cell. 2006;10(4):257-268.
43. Margueron R, Reinberg D. The Polycomb complex PRC2 and its mark in life. Nature. 2011;469(7330):343-349.
44. Tan J, Yang X, Zhuang L, et al. Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev. 2007;21(9):1050-1063.
45. Ueda K, Yoshimi A, Kagoya Y, et al. Inhibition of histone methyltransferase EZH2 depletes leukemia stem cell of mixed lineage leukemia fusion leukemia through upregulation of p16. Cancer Sci. 2014;105(5):512-519.
46. Miranda TB, Cortez CC, Yoo CB, et al. DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation. Mol Cancer Ther. 2009;8(6):1579-1588.
47. Lee JK, Kim KC. DZNep, inhibitor of S-adenosylhomocysteine hydrolase, downregulates expression of SETDB1 H3K9me3 HMTase in human lung cancer cells. Biochem Biophys Res Commun. 2013;438(4):647-652.
48. Garapaty-Rao S, Nasveschuk C, Gagnon A, et al. Identification of EZH2 and EZH1 small molecule inhibitors with selective impact on diffuse large B cell lymphoma cell growth. Chem Biol. 2013;20(11):1329-1339.
49. Knutson SK, Warholic NM, Wigle TJ, et al. Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2. Proc Natl Acad Sci USA. 2013;110(19):7922-7927.
50. Kim W, Bird GH, Neff T, et al. Targeted disruption of the EZH2-EED complex inhibits EZH2-dependent cancer. Nat Chem Biol. 2013;9(10):643-650.
51. Simon C, Chagraoui J, Krosl J, et al. A key role for EZH2 and associated genes in mouse and human adult T-cell acute leukemia. Genes Dev. 2012;26(7):651-656.
52. Shih AH, Abdel-Wahab O, Patel JP, Levine RL. The role of mutations in epigenetic regulators in myeloid malignancies. Nat Rev Cancer. 2012;12(9):599-612.
53. Zuber J, Shi J, Wang E, et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature. 2011;478(7370):524-528.
54. Filippakopoulos P, Qi J, Picaud S, et al. Selective inhibition of BET bromodomains. Nature. 2010;468(7327):1067-1073.
55. Daigle SR, Olhava EJ, Therkelsen CA, et al. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell. 2011;20(1):53-65.